A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

A Systems Biology Phase 1 Evaluation of the Safety, Reactogenicity, and Immunogenicity of Chimpanzee Adenovirus Type 3- Vectored Zaire Ebolavirus (ChAd3-EBO-Z) and Modified Vaccinia Ankara- Vectored Multivalent Filovirus (MVA-BN(R)-Filo) Vaccine Candidates

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03583606

Enrollment

Registered

2018-07-11

Start date

2018-11-12

Completion date

2020-01-14

Last updated

2025-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ebola Disease, Immunisation

Keywords

Adenovirus vector, Ebola Virus, Immunogenicity, Non-Human Primates Vaccination/Challenge Studies, Phase 1, Reactogenicity, Safety, Zaire ebolavirus vaccine

Brief summary

This initial, proof of concept study will focus on identifying significant differences in response to the Ebolavirus Zaire vaccine (ChAd3-EBO-Z) when administered with placebo, MVA-BN(R)-Filo, or ChAd3-EBO-Z boosters after 8 days. All 60 participants will receive the ChAd3-EBO-Z vaccine and then randomized into each booster group (20 receiving each type of booster). Subjects will be followed-up for 6 months to monitor for safety outcomes and efficacy measures. There is no formal hypothesis for this study. The primary objective of this study is to assess the safety and reactogenicity of study products by study group when administered IM to healthy adults.

Detailed description

This is a Phase 1, randomized, double-blind trial of 60 evaluable males and non-pregnant females, 18-45 years old, inclusive, who are in good health, meet all eligibility criteria, and do not meet any exclusion criteria. This trial is designed to assess the safety, reactogenicity and immunogenicity of an Ebolavirus Zaire (ChAd3-EBO-Z) vaccine for the prevention of Ebola. ChAd3-EBO-Z will be administered intramuscularly into the deltoid of all participants on Day 1. On Day 8, subjects will receive either placebo, ChAd3-EBO-Z , or MVA- BN(R)-Filo boosters, administered intramuscularly into the deltoid of the arm opposite their first vaccination, based on study group. There will be 20 subjects in each group. Subjects will be monitored for 6 months after vaccination to assess safety and efficacy for ChA3d-EBO-Z with homologous and heterologous boosting. Differences between the homologous and heterologous arm represent potential points for further, more in depth assessment to determine if there is a correlation with efficacy. Long term goals include comparing results from this study with results from naturally infected individuals as well as non-human primate (NHP) vaccination/challenge studies. There is no formal hypothesis for this study. The primary objective of this study is to assess the safety and reactogenicity of study products by study group when administered IM to healthy adults. The secondary study objective is to assess the antibody response to Zaire ebolavirus (EBOV) glycoprotein (GP) by study group.

Interventions

BIOLOGICALChAd3-EBO-Z

Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)).

BIOLOGICALMVA Multi-Filo Ebola Vaccine

A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10\^8 Infectious Units (IU).

OTHERPlacebo

0.5 mL normal saline administered via IM injection into the deltoid.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

1. Provide written informed consent before initiation of any study procedures. 2. Are able to understand and comply with planned study procedures and be available for all study visits/phone calls. 3. Males or non-pregnant females ages 18-45, inclusive. 4. Subject must have a body mass index (BMI) \> / = 18.5 and \< 35 kg/m\^2. 5. Are in good health. * As determined by medical history and physical examination to evaluate acute or currently ongoing chronic medical diagnoses or conditions, defined as those that have been present for at least 90 days which would affect the assessment of the safety of subjects or the immunogenicity of study vaccinations. Chronic medical diagnoses or conditions should be stable for the last 60 days (no hospitalizations, ER or urgent care for condition and no adverse symptoms that need medical intervention such as medication change/supplemental oxygen). This includes no change in chronic prescription medication, dose, or frequency as a result of deterioration of the chronic medical diagnosis or condition in the 60 days prior to enrollment. Any prescription change that is due to change of health care provider, insurance company, etc., or that is done for financial reasons, as long as in the same class of medication, will not be considered a deviation of this inclusion criterion. Any change in prescription medication due to improvement of a disease outcome, as determined by the site principal investigator or appropriate sub-investigator, will not be considered a deviation of this inclusion criterion. Subjects may be on chronic or as needed (prn) medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity and do not indicate a worsening of medical diagnosis or condition. Similarly, medication changes subsequent to enrollment and study vaccination are acceptable provided there was no deterioration in the subject's chronic medical condition that necessitated a medication change, and there is no additional risk to the subject or interference with the evaluation of responses to study vaccination. Note: Topical, nasal, and inhaled medications (apart from steroids as outlined in the Subject

Exclusion criteria

), herbals, vitamins, and supplements are permitted. 6. Oral temperature is less than 100.0 degrees Fahrenheit (37.8 degrees Celsius). 7. Pulse is 47 to 105 beats per minute (bpm), inclusive. 8. Systolic blood pressure (BP) is 85 to 150 mm Hg, inclusive. 9. Diastolic blood pressure (BP) is 55 to 95 mm Hg, inclusive. 10. Have acceptable screening laboratories within 28 days prior to enrollment * Screening labs include white blood cell (WBC), Hgb, platelet count, ANC, sodium, potassium, creatinine, albumin, total protein, PT, PTT, alanine aminotransferase (ALT). Blood Urea Nitrogen (BUN) will be obtained only if creatinine is above normal range. * Screening laboratory values that are outside the range of eligibility but are thought to be due to an acute condition or due to laboratory error may be repeated once. 11. Have normal screening laboratories for urine protein. Trace protein is acceptable. 12. Drug screen for opiates is negative. 13. Hemoglobin A1C (HgbA1C) \< 6.3% at screening. 14. HIV 1/2 antibody negative. 15. HCV antibody negative. 16. HBsAg negative. 17. Women of childbearing potential, must be using an effective method of contraception from 30 days prior to the first study vaccination until 90 days after the second study vaccination. \- Women of childbearing potential are not sterilized via tubal ligation, bilateral oophorectomy, hysterectomy, successful Essure(R) placement (permanent, non-surgical, non-hormonal sterilization) with history of documented radiological confirmation test at least 90 days after the procedure (or with use of another birth control method if history of confirmation test not confirmed), still menstruating, or \< 1 year of the last menses if menopausal. \-- Effective methods of contraception includes, but is not limited to, non-male sexual relationships, abstinence from sexual intercourse with a male partner, monogamous relationship with a vasectomized partner, male condoms with the use of applied spermicide, intrauterine devices, NuvaRing(R), and licensed hormonal methods such as implants, injectables or oral contraceptives (the pill). 18. Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to each study vaccination. 19. Women agree to not donate eggs (ova, oocytes) from the start of screening onwards until at least 90 days after the second vaccination. 20. Agrees not to participate in another clinical trial during the study period. 21. Agrees not to donate blood to a blood bank for 3 months after receiving the second study vaccine.

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Day 1 to approximately 28 Days Post Second Vaccination	Vaccine-related unsolicited AEs include any untoward medical occurrence in a participant for which there is evidence to suggest a causal relationship between the study product and the adverse event. Thresholds for severity include events require minimal or no treatment and do not interfere with the subject's daily activities (mild), events result in a low level of inconvenience or concern with therapeutic measures and may cause some interference with functioning and daily activities (moderate), and events interrupt the subject's daily activities and may require systemic drug therapy or other treatment and are usually incapacitating (severe). Participants are counted once per preferred term and are summarized according to their highest severity. No severe events were reported.
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 1 to approximately 28 Days Post Second Vaccination	Thresholds for adverse events were considered as creatinine 0.81 - 1.70 mg/dL (female) or 1.11 - 1.70 mg/dL (male) (mild), 1.71 - 2.00 mg/dL (moderate), \>2.00 mg/dL (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 1 to approximately 28 Days Post Second Vaccination	Thresholds for adverse events were considered as sodium 130 - 135 mmol/L or 146 - 150 mmol/L (mild), 123 - 129 mmol/L or 151 - 157 mmol/L (moderate), \<123 mmol/L or \>157 mmol/L (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 1 to approximately 28 Days Post Second Vaccination	Thresholds for adverse events were considered as potassium 3.0 - 3.4 mmol/L or 5.2 - 6.0 mmol/L (mild), 2.5 - 2.9 mmol/L or 6.1 - 6.5 mmol/L (moderate), \<2.5 mmol/L or \>6.5 mmol/L (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 1 to approximately 28 Days Post Second Vaccination	Thresholds for adverse events were considered as BUN 24 - 26 mg/dL (mild), 27 - 31 mg/dL (moderate), \>31 mg/dL (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.
Number of Participants by Severity of Solicited Local Reactogenicity	Day 1 to Day 8 Post First Vaccination	Local reactogenicity solicited on memory aid include pain; tenderness; pruritus (itch); erythema (redness), induration (hardness/swelling), and ecchymosis (bruising) (functional and measurement). Thresholds for severity were pain: aware, no interference with activity, no pain med (mild), aware, interferes with activity or requires repeated use of a non-narcotic pain reliever for \>24 hr (moderate), aware, prevents activity or requires prescription med use (severe); tenderness: area surrounding injection hurts when touched or with arm motion, no interference with daily activity (mild), hurts when touched or with arm motion, interferes with activity (moderate), hurts when touched or with arm motion and prevents activity (severe); functional erythema, induration, ecchymosis, and pruritus: no activity interference (mild), interferes with activity (moderate), prevents activity (severe); erythema, induration, and ecchymosis (measurement): \<20mm (mild), 20 - 50mm (moderate), \>50mm (severe).
Number of Participants by Severity of Solicited Systemic Reactogenicity	Day 1 to Day 8 Post First Vaccination	Systemic reactogenicity solicited on memory aid included feverishness (chills/shivering/sweating), malaise (general unwell feeling), fatigue (tiredness), myalgia (body aches/muscular pain not at injection site), headache, nausea, loss of appetite, and elevated oral temperature. Thresholds for severity include feverishness, malaise, fatigue, myalgia, nausea, and loss of appetite: Noticeable but does not interfere with daily activity (Mild), Interferes with daily activity (Moderate), Significant interference, prevents daily activity (Severe); headache: Noticeable but does not interfere with daily activity (Mild), Any use of pain reliever or interferes with daily activity (Moderate), Significant interference, prevents daily activity, or requires any use of a prescription medication (Severe); elevated oral temperature: 37.8°C - 38.4°C or 100.00°F - 101.1°F (Mild), 38.5°C - 38.9°C or 101.2°F - 102.0°F (Moderate), \>38.9°C or \>102.0°F (Severe).
Number of Participants With Clinical Safety Laboratory Adverse Events	Day 1 to approximately 28 Days Post Second Vaccination	Laboratory parameters include white blood cells (WBC), hemoglobin, platelet count, absolute neutrophil count, alanine aminotransferase (ALT), creatinine, sodium, potassium and blood urea nitrogen (BUN). Thresholds for adverse events were considered as WBC \<= 4.4 K/mcL or \>=13.1 K/mcL (18 to \<21 years) or \<= 4.4 K/mcL or \>= 11.1 K/mcL (\>=21 years), hemoglobin \<= 11.6 g/dL (female) or \<= 13.2 g/dL (male), platelet count \<= 134 K/mcL or \>= 467 K/mcL, absolute neutrophil count \<1.8 K/mcL or \<=0.7 K/mcL (benign ethnic neutropenia), ALT \>= 50 unit/L, creatinine \>= 0.81 mg/dL (female) or \>= 1.11 mg/dL (male), sodium \<= 135 mmol/L or \>= 146 mmol/L, potassium \<= 3.4 mmol/L or \>= 5.2 mmol/L and BUN \>= 24 mg/dL. If baseline clinical labs fell within Mild range, then a laboratory AE was reported only if the value changed such that it fell into Moderate range or higher when subsequent safety laboratory testing was done.
Number of Participants Reporting Serious Adverse Events (SAEs)	Day 1 to Day 182	SAEs included any AE that resulted in death, a life-threatening event, an inpatient hospitalization or prolongation of existing hospitalization, a persistent/significant disability/incapacity, or a congenital anomaly/birth defect.
Number of Participants Reporting Solicited Local Reactogenicity	Day 1 to Day 8 Post First Vaccination	Local reactogenicity solicited on a memory aid provided to participants included pain, tenderness, erythema (redness) (functional grade based on interference with daily activities), induration (hardness/swelling) (functional grade), ecchymosis (bruising) (functional grade), pruritus (itching), erythema (redness) (any measured value), induration (hardness/swelling) (any measured value), ecchymosis (bruising) (any measured value). Participants are considered reporting the local reactogenicity if they reported mild or greater severity at any time during the 7 days post-vaccination.
Number of Participants Reporting Solicited Systemic Reactogenicity	Day 1 to Day 8 Post First Vaccination	Systemic reactogenicity solicited on a memory aid provided to participants included feverishness (chills/shivering/sweating), malaise (general unwell feeling), fatigue (tiredness), myalgia (body aches/muscular pain not at injection site), headache, nausea, loss of appetite, and elevated oral temperature. Participants are considered reporting the systemic reactogenicity if they reported mild or greater severity at any time during the 7 days post-vaccination.
Number of Participants Reporting Vaccine-related Medically Attended Adverse Events (MAAEs)	Day 1 to Day 182	Vaccine-related MAAEs include any AEs for which the participant received medical attention, defined as hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel for any reason for which there is evidence to suggest a causal relationship between the study product and the adverse event.
Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Day 1 to approximately 28 Days Post Second Vaccination	Vaccine-related unsolicited AEs include any untoward medical occurrence in a participant for which there is evidence to suggest a causal relationship between the study product and the adverse event.
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 1 to approximately 28 Days Post Second Vaccination	Thresholds for adverse events were considered as WBC 2.5 - 4.4 K/mcL or 13.1 - 15.0 K/mcL (18 to \<21 years) or 2.5 - 4.4 K/mcL or 11.1 - 15.0 (\>=21 years) (mild), 1.5 - 2.4 K/mcL or 15.1 - 20.0 K/mcL (moderate), \<1.5 K/mcL or \>20.0 K/mcL (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 1 to approximately 28 Days Post Second Vaccination	Thresholds for adverse events were considered as hemoglobin 10.1 - 11.6 g/dL (female) or 11.0 - 13.2 (male) (mild), 8.5 - 10 g/dL (female) or 9.5 - 10.9 g/dL (male) (moderate), \<8.5 g/dL (female) or \<9.5 g/dL (male) (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 1 to approximately 28 Days Post Second Vaccination	Thresholds for adverse events were considered as platelet count 125 - 134 K/mcL or 467 - 517 K/mcL (mild), 100 - 124 K/mcL or 518 - 750 K/mcL (moderate), \<100 K/mcL or \>750 K/mcL (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 1 to approximately 28 Days Post Second Vaccination	Thresholds for adverse events were considered as absolute neutrophil count 1.5 - \<1.8 K/mcL or 0.6 - 0.7 K/mcL (benign ethnic neutropenia) (mild), 1.0 - \<1.5 K/mcL or 0.4 - 0.5 K/mcL (benign ethnic neutropenia) (moderate), \<1.0 K/mcL or \<0.4 K/mcL (benign ethnic neutropenia) (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.
Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 1 to approximately 28 Days Post Second Vaccination	Thresholds for adverse events were considered as 50 - 123 unit/L (mild), 124 - 245 unit/L (moderate), \>245 unit/L (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.

Secondary

Measure	Time frame	Description
Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8, 15, 22, 29 and 36 compared to baseline (Day 1) reported as Day 8 post-first vaccination, Day 8 post-second vaccination, Day 15 post-second vaccination, Day 22 post-second vaccination, and Day 29 post-second vaccination, respectively.	The endpoint assessed antibodies against Ebola virus (EBOV) glycoproteins (GP) using an enzyme-linked immunosorbent assay (anti-EBOV GP ELISA). Venous blood samples for serum were used for this assay. Geometric mean fold rise (GMFR) compared to baseline (Day 1) was calculated for each study arm.
Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 8, 15, 22, 29 and 36 compared to baseline (Day 1) reported as Day 8 post-first vaccination, Day 8 post-second vaccination, Day 15 post-second vaccination, Day 22 post-second vaccination, and Day 29 post-second vaccination, respectively.	The endpoint assessed antibodies against Ebola virus (EBOV) glycoproteins (GP) using an enzyme-linked immunosorbent assay (anti-EBOV GP ELISA). Venous blood samples for serum were used for this assay. Geometric mean fold rise (GMFR) compared to baseline (Day 1) was calculated for each study arm.
Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 1, 8, 15, 22, 29 and 36 reported as Day 1 first vaccination, Day 8 post-first vaccination, Day 8 post-second vaccination, Day 15 post-second vaccination, Day 22 post-second vaccination, and Day 29 post-second vaccination, respectively.	The endpoint assessed antibodies against Ebola virus (EBOV) glycoproteins (GP) using an enzyme-linked immunosorbent assay (anti-EBOV GP ELISA). Venous blood samples for serum were used for this assay. Geometric Mean Titer (GMT) was calculated for each study arm.
Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8, 15, 22, 29 and 36 reported as Day 8 post-first vaccination, Day 8 post-second vaccination, Day 15 post-second vaccination, Day 22 post-second vaccination, and Day 29 post-second vaccination, respectively.	The endpoint assessed antibodies against Ebola virus (EBOV) glycoproteins (GP) using an enzyme-linked immunosorbent assay (anti-EBOV GP ELISA). Venous blood samples for serum were used for this assay. Seroconversion was calculated for each study arm and was defined as anti-EBOV GP ELISA titer \> 50 if baseline (Day 1) titer = 50 or fold rise \> 4 as compared to baseline if baseline titer \> 50.
Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8, 15, 22, 29 and 36 reported as Day 8 post-first vaccination, Day 8 post-second vaccination, Day 15 post-second vaccination, Day 22 post-second vaccination, and Day 29 post-second vaccination, respectively.	The endpoint assessed antibodies against Ebola virus (EBOV) glycoproteins (GP) using an enzyme-linked immunosorbent assay (anti-EBOV GP ELISA). Venous blood samples for serum were used for this assay. Seroconversion was calculated for each study arm and was defined as anti-EBOV GP ELISA titer \> 50 if baseline (Day 1) titer = 50 or fold rise \> 4 as compared to baseline if baseline titer \> 50.
Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 1, 8, 15, 22, 29 and 36 reported as Day 1 first vaccination, Day 8 post-first vaccination, Day 8 post-second vaccination, Day 15 post-second vaccination, Day 22 post-second vaccination, and Day 29 post-second vaccination, respectively.	The endpoint assessed antibodies against Ebola virus (EBOV) glycoproteins (GP) using an enzyme-linked immunosorbent assay (anti-EBOV GP ELISA). Venous blood samples for serum were used for this assay. Geometric Mean Titer (GMT) was calculated for each study arm.

Countries

United States

Participant flow

Recruitment details

Participants were males and non-pregnant females in good health, aged 19 to 45, and recruited from the community at large at the participating site. Participants were enrolled between 12NOV2018 to 10JUL2019.

Participants by arm

Arm	Count
ChAd3-EBO-Z + Placebo ChAd3-EBO-Z (2 x 10\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and placebo intramuscularly into the opposite arm on Day 8. ChAd3-EBO-Z: Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)). Placebo: 0.5 mL normal saline administered via IM injection into the deltoid.	22
ChAd3-EBO-Z + ChAd3-EBO-Z ChAd3-EBO-Z (2 x 10\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and ChAd3-EBO-Z (2 x 10\^11 vp) intramuscularly into the opposite arm on Day 8. ChAd3-EBO-Z: Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)).	20
ChAd3-EBO-Z + MVA- BN-Filo ChAd3-EBO-Z (2 x 10\^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and MVA-BN-Filo (1 x 10\^8 Infectious Units (IU)) intramuscularly into the opposite arm on Day 8. ChAd3-EBO-Z: Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)). MVA Multi-Filo Ebola Vaccine: A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10\^8 Infectious Units (IU).	19
Total	61

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Overall Study	Ineligible at baseline	1	0	0
Overall Study	Lost to Follow-up	0	1	0

Baseline characteristics

Characteristic	ChAd3-EBO-Z + Placebo	ChAd3-EBO-Z + ChAd3-EBO-Z	ChAd3-EBO-Z + MVA- BN-Filo	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical Between 18 and 65 years	22 Participants	20 Participants	19 Participants	61 Participants
Age, Continuous	33.8 Years STANDARD_DEVIATION 7.8	26.8 Years STANDARD_DEVIATION 5.3	31.4 Years STANDARD_DEVIATION 7.6	30.8 Years STANDARD_DEVIATION 7.5
BMI	26.35 kg/m^2 STANDARD_DEVIATION 3.96	25.19 kg/m^2 STANDARD_DEVIATION 3.77	25.49 kg/m^2 STANDARD_DEVIATION 4.06	25.70 kg/m^2 STANDARD_DEVIATION 3.9
Ethnicity (NIH/OMB) Hispanic or Latino	3 Participants	1 Participants	2 Participants	6 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	19 Participants	19 Participants	17 Participants	55 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	1 Participants	0 Participants	2 Participants	3 Participants
Race (NIH/OMB) Black or African American	3 Participants	0 Participants	2 Participants	5 Participants
Race (NIH/OMB) More than one race	2 Participants	1 Participants	0 Participants	3 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	16 Participants	19 Participants	15 Participants	50 Participants
Region of Enrollment United States	22 participants	20 participants	19 participants	61 participants
Sex: Female, Male Female	11 Participants	11 Participants	13 Participants	35 Participants
Sex: Female, Male Male	11 Participants	9 Participants	6 Participants	26 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	0 / 21	0 / 20	0 / 19
other Total, other adverse events	21 / 21	20 / 20	19 / 19
serious Total, serious adverse events	0 / 21	0 / 20	0 / 19

Outcome results

Primary

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count

Thresholds for adverse events were considered as absolute neutrophil count 1.5 - \<1.8 K/mcL or 0.6 - 0.7 K/mcL (benign ethnic neutropenia) (mild), 1.0 - \<1.5 K/mcL or 0.4 - 0.5 K/mcL (benign ethnic neutropenia) (moderate), \<1.0 K/mcL or \<0.4 K/mcL (benign ethnic neutropenia) (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	None	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Missing	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	None	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	None	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Mild	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	None	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Mild	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	None	15 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Mild	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Moderate	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Moderate	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	None	16 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Moderate	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Max Severity Post Baseline	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 29 Post-Second Vaccination	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count	Day 8 (Second Vaccination)	Mild	0 Participants

Primary

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT

Thresholds for adverse events were considered as 50 - 123 unit/L (mild), 124 - 245 unit/L (moderate), \>245 unit/L (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	None	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	None	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	None	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Max Severity Post Baseline	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 22 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 29 Post-Second Vaccination	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT	Day 8 (Second Vaccination)	Moderate	0 Participants

Primary

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN

Thresholds for adverse events were considered as BUN 24 - 26 mg/dL (mild), 27 - 31 mg/dL (moderate), \>31 mg/dL (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Missing	18 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	None	4 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	None	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	None	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Missing	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Missing	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Missing	18 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	None	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	None	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Missing	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	None	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Missing	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	None	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Missing	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	None	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Missing	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	None	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Missing	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	None	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Missing	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	None	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	None	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Missing	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	Missing	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	None	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 (Second Vaccination)	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	None	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Missing	15 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 22 Post-Second Vaccination	Missing	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Missing	15 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Max Severity Post Baseline	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 29 Post-Second Vaccination	None	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN	Day 8 Post-Second Vaccination	Severe	0 Participants

Primary

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)

Thresholds for adverse events were considered as creatinine 0.81 - 1.70 mg/dL (female) or 1.11 - 1.70 mg/dL (male) (mild), 1.71 - 2.00 mg/dL (moderate), \>2.00 mg/dL (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Mild	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	None	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Mild	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	None	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	None	16 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Mild	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Mild	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)	Max Severity Post Baseline	Severe	0 Participants

Primary

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin

Thresholds for adverse events were considered as hemoglobin 10.1 - 11.6 g/dL (female) or 11.0 - 13.2 (male) (mild), 8.5 - 10 g/dL (female) or 9.5 - 10.9 g/dL (male) (moderate), \<8.5 g/dL (female) or \<9.5 g/dL (male) (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Mild	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Mild	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	None	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	None	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Mild	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	None	16 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	None	14 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Mild	5 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	None	15 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Mild	4 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Mild	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	None	14 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Mild	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Mild	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Max Severity Post Baseline	Mild	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 22 Post-Second Vaccination	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 29 Post-Second Vaccination	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin	Day 8 (Second Vaccination)	Moderate	0 Participants

Primary

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count

Thresholds for adverse events were considered as platelet count 125 - 134 K/mcL or 467 - 517 K/mcL (mild), 100 - 124 K/mcL or 518 - 750 K/mcL (moderate), \<100 K/mcL or \>750 K/mcL (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Mild (high)	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Moderate (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Moderate (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	None	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Moderate (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Mild (low)	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Mild (low)	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Moderate (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Moderate (low)	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	Moderate (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 (Second Vaccination)	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Max Severity Post Baseline	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 29 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count	Day 8 Post-Second Vaccination	Moderate (low)	0 Participants

Primary

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium

Thresholds for adverse events were considered as potassium 3.0 - 3.4 mmol/L or 5.2 - 6.0 mmol/L (mild), 2.5 - 2.9 mmol/L or 6.1 - 6.5 mmol/L (moderate), \<2.5 mmol/L or \>6.5 mmol/L (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Mild (high)	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Mild (high)	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Mild (high)	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Mild (high)	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 Post-Second Vaccination	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 8 (Second Vaccination)	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Day 29 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium	Max Severity Post Baseline	Mild (low)	0 Participants

Primary

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium

Thresholds for adverse events were considered as sodium 130 - 135 mmol/L or 146 - 150 mmol/L (mild), 123 - 129 mmol/L or 151 - 157 mmol/L (moderate), \<123 mmol/L or \>157 mmol/L (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Mild (high)	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Mild (high)	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Mild (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Severe (low or high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Moderate (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 (Second Vaccination)	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Max Severity Post Baseline	Severe (low or high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 29 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium	Day 8 Post-Second Vaccination	Moderate (low or high)	0 Participants

Primary

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells

Thresholds for adverse events were considered as WBC 2.5 - 4.4 K/mcL or 13.1 - 15.0 K/mcL (18 to \<21 years) or 2.5 - 4.4 K/mcL or 11.1 - 15.0 (\>=21 years) (mild), 1.5 - 2.4 K/mcL or 15.1 - 20.0 K/mcL (moderate), \<1.5 K/mcL or \>20.0 K/mcL (severe). If baseline clinical labs fell within mild range, then a laboratory AE was reported only if the value changed such that it fell into moderate range or higher when subsequent safety laboratory testing was done.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all Participants who received at least one study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Moderate (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	None	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	None	19 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Moderate (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Moderate (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Mild (low)	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Mild (low)	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Moderate (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Mild (low)	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Moderate (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Moderate (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Mild (low)	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Mild (low)	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Moderate (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	None	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Mild (low)	4 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Mild (low)	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Moderate (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Moderate (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	None	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Mild (low)	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Mild (high)	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Moderate (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	None	16 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Mild (low)	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Mild (high)	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Moderate (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	None	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Mild (low)	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Moderate (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	None	15 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Mild (high)	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Moderate (low)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Moderate (high)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Mild (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Mild (low)	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Moderate (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Moderate (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Moderate (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Moderate (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Mild (low)	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 29 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Missing	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 (Second Vaccination)	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Moderate (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Moderate (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Moderate (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Moderate (low)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	None	15 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 22 Post-Second Vaccination	Missing	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Day 8 Post-Second Vaccination	Mild (high)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells	Max Severity Post Baseline	Mild (low)	4 Participants

Primary

Number of Participants by Severity of Solicited Local Reactogenicity

Local reactogenicity solicited on memory aid include pain; tenderness; pruritus (itch); erythema (redness), induration (hardness/swelling), and ecchymosis (bruising) (functional and measurement). Thresholds for severity were pain: aware, no interference with activity, no pain med (mild), aware, interferes with activity or requires repeated use of a non-narcotic pain reliever for \>24 hr (moderate), aware, prevents activity or requires prescription med use (severe); tenderness: area surrounding injection hurts when touched or with arm motion, no interference with daily activity (mild), hurts when touched or with arm motion, interferes with activity (moderate), hurts when touched or with arm motion and prevents activity (severe); functional erythema, induration, ecchymosis, and pruritus: no activity interference (mild), interferes with activity (moderate), prevents activity (severe); erythema, induration, and ecchymosis (measurement): \<20mm (mild), 20 - 50mm (moderate), \>50mm (severe).

Time frame: Day 1 to Day 8 Post First Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination. All participants in all Study Arms received the same product (ChAd3-EBO-Z) at Day 1.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	None	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Mild	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Moderate	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	None	8 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Mild	11 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Moderate	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	None	4 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Mild	16 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	None	14 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Mild	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	None	14 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Mild	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	None	15 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Mild	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	None	15 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Mild	5 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Mild	5 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	None	13 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Mild	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	None	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Mild	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	None	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Mild	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	None	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Mild	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	None	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	None	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Mild	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Moderate	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	None	13 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Mild	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	None	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Mild	15 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Moderate	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	None	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Mild	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Severe	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	None	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Mild	10 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Mild	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	None	14 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Mild	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Mild	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Mild	10 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	None	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Mild	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	None	14 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	None	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Mild	11 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	None	8 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Moderate	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Moderate	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Moderate	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	None	8 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Mild	11 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Severe	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Severe	1 Participants

Primary

Number of Participants by Severity of Solicited Local Reactogenicity

Local reactogenicity solicited on memory aid include pain; tenderness; pruritus (itch); erythema (redness), induration (hardness/swelling), and ecchymosis (bruising) (functional and measurement). Thresholds for severity grading were pain: aware, no interference with activity, no pain med (mild), aware, interferes with activity or requires repeated use of a non-narcotic pain reliever for \>24hr (moderate), aware, prevents activity or requires prescription med use (severe); tenderness: area surrounding injection hurts when touched or with arm motion, no interference with daily activity (mild), hurts when touched or with arm motion, interferes with activity (moderate), hurts when touched or with arm motion, prevents activity (severe); functional erythema, induration, ecchymosis, and pruritus: no activity interference (mild), interferes with activity (moderate), prevents activity (severe); erythema, induration, and ecchymosis (measurement): \<20mm (mild), 20-50mm (moderate), \>50mm (severe).

Time frame: Day 1 to Day 8 Post Second Vaccination

Population: Safety Population Subset: includes all participants who received the first and second study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	None	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	None	12 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	None	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Mild	5 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	None	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	None	16 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	None	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Mild	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	None	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Mild	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	None	12 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	None	14 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	None	11 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Mild	5 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Mild	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Mild	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	None	16 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	None	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	None	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	None	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Mild	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	None	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	None	14 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Mild	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	None	14 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	None	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Mild	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Moderate	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	None	4 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Mild	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Moderate	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	None	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Mild	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Moderate	5 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Severe	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Mild	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	None	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	None	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	None	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Mild	13 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Measurement grade)	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any Local Symptom	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Mild	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	None	13 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Mild	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	Mild	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Measurement grade)	None	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (Functional grade)	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (Functional grade)	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (Measurement grade)	Moderate	0 Participants

Primary

Number of Participants by Severity of Solicited Local Reactogenicity

Local reactogenicity solicited on memory aid include pain; tenderness; pruritus (itch); erythema (redness), induration (hardness/swelling), and ecchymosis (bruising) (functional and measurement). Thresholds for severity grading were pain: aware, no interference with activity, no pain med (mild), aware, interferes with activity or requires repeated use of a non-narcotic pain reliever for \>24hr (moderate), aware, prevents activity or requires prescription med use (severe); tenderness: area surrounding injection hurts when touched or with arm motion, no interference with daily activity (mild), hurts when touched or with arm motion, interferes with activity (moderate), hurts when touched or with arm motion, prevents activity (severe); functional erythema, induration, ecchymosis, and pruritus: no activity interference (mild), interferes with activity (moderate), prevents activity (severe); erythema, induration, and ecchymosis (measurement): \<20mm (mild), 20-50mm (moderate), \>50mm (severe).

Time frame: Day 1 to Day 15

Population: Safety Population: includes all participants who received at least one study vaccination.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	Moderate	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	None	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Mild	11 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Moderate	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	None	8 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Mild	16 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	Mild	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	None	4 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	Mild	10 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	None	11 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	Mild	10 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	None	11 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	Mild	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	None	15 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	Mild	5 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	None	15 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	None	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	None	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	Mild	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	Mild	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	None	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	Mild	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	None	12 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	Mild	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	None	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	Mild	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	Moderate	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	None	12 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	Severe	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	None	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Mild	15 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	Mild	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Moderate	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	None	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Mild	12 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Moderate	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	None	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	Mild	10 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Severe	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	Mild	11 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	None	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	None	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	Moderate	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	Mild	11 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (functional)	Mild	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	Severe	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	None	14 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Erythema (measured)	None	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Mild	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Any local symptom	None	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	Mild	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	Moderate	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Mild	10 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	None	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Tenderness	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (functional)	None	14 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (measured)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Moderate	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	Mild	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Ecchymosis (functional)	Mild	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pruritus	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Induration (measured)	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Local Reactogenicity	Pain	Severe	1 Participants

Primary

Number of Participants by Severity of Solicited Systemic Reactogenicity

Systemic reactogenicity solicited on memory aid included feverishness (chills/shivering/sweating), malaise (general unwell feeling), fatigue (tiredness), myalgia (body aches/muscular pain not at injection site), headache, nausea, loss of appetite, and elevated oral temperature. Thresholds for severity include feverishness, malaise, fatigue, myalgia, nausea, and loss of appetite: Noticeable but does not interfere with daily activity (Mild), Interferes with daily activity (Moderate), Significant interference, prevents daily activity (Severe); headache: Noticeable but does not interfere with daily activity (Mild), Any use of pain reliever or interferes with daily activity (Moderate), Significant interference, prevents daily activity, or requires any use of a prescription medication (Severe); elevated oral temperature: 37.8°C - 38.4°C or 100.00°F - 101.1°F (Mild), 38.5°C - 38.9°C or 101.2°F - 102.0°F (Moderate), \>38.9°C or \>102.0°F (Severe).

Time frame: Day 1 to Day 15

Population: Safety Population: includes all participants who received at least one study vaccination.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Mild	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	None	4 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Mild	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	None	14 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Moderate	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Mild	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Moderate	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Mild	10 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	None	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Severe	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Mild	13 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Moderate	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	None	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Moderate	5 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Moderate	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Severe	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Moderate	8 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Mild	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	None	10 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Severe	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	None	8 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Mild	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	None	15 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Moderate	8 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Mild	4 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Moderate	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Severe	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	None	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Mild	11 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	None	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	None	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Moderate	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Mild	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Severe	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	None	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Mild	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Moderate	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Severe	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	None	8 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Mild	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Moderate	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Severe	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	None	4 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Mild	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Moderate	5 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Severe	4 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	None	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Mild	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Moderate	8 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Severe	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	None	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Mild	8 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Severe	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	None	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Mild	5 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Moderate	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	None	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Mild	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Moderate	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Moderate	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Mild	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	None	8 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Severe	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Severe	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Mild	8 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Moderate	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Moderate	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Mild	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Mild	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	None	10 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Mild	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	None	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Severe	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Moderate	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Moderate	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Moderate	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Moderate	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Mild	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Moderate	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	None	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Severe	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Mild	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	None	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Severe	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	None	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Mild	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Moderate	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Moderate	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Mild	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	None	11 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Severe	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	None	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	None	16 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	None	7 Participants

Primary

Number of Participants by Severity of Solicited Systemic Reactogenicity

Time frame: Day 1 to Day 8 Post First Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination. All participants in all Study Arms received the same product (ChAd3-EBO-Z) at Day 1.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Severe	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	None	8 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	None	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Moderate	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Mild	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	None	10 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Mild	11 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Moderate	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Mild	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	None	4 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Severe	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	None	4 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Mild	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Moderate	4 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Mild	13 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	None	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Mild	5 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Moderate	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Moderate	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	None	15 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Severe	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Moderate	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	None	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Mild	5 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Mild	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Mild	9 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Moderate	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Severe	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	None	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Severe	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Mild	8 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	None	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Mild	8 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Moderate	5 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	None	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Moderate	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Severe	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	None	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Mild	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Moderate	5 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Severe	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	None	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Mild	8 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Moderate	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Severe	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	None	5 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Mild	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Moderate	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Severe	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	None	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Mild	8 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Moderate	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Severe	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	None	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Mild	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Moderate	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	None	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Mild	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Moderate	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	None	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Severe	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Severe	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Severe	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Moderate	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	None	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	None	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Mild	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	None	11 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Mild	8 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	None	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Moderate	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Moderate	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Severe	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Mild	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Moderate	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Mild	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	None	16 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Mild	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Mild	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	None	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Mild	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Moderate	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Severe	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Moderate	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Severe	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Moderate	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	None	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Mild	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	None	10 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Mild	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	None	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Moderate	4 Participants

Primary

Number of Participants by Severity of Solicited Systemic Reactogenicity

Time frame: Day 1 to Day 8 Post Second Vaccination

Population: Safety Population Subset: includes all participants who received the first and second study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	None	14 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Mild	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Mild	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	None	10 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	None	9 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	None	14 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	None	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	None	10 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Mild	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Mild	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Mild	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	None	15 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Mild	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	None	14 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	None	14 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Mild	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Moderate	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Mild	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Severe	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Moderate	4 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	None	8 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Mild	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Moderate	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	None	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	None	13 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Mild	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Mild	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Moderate	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	None	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Moderate	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Mild	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Severe	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	None	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Severe	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Mild	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	None	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	None	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	None	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Mild	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Moderate	4 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Mild	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Severe	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	None	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Mild	4 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Moderate	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Mild	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Mild	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Moderate	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Elevated Oral Temperature	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Feverishness	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Malaise	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	None	15 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Mild	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Fatigue	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	None	14 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Mild	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Myalgia	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	None	14 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Mild	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Headache	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	None	17 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Moderate	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Nausea	Severe	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Loss of Appetite	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Solicited Systemic Reactogenicity	Any Systemic Symptom	None	12 Participants

Primary

Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)

Vaccine-related unsolicited AEs include any untoward medical occurrence in a participant for which there is evidence to suggest a causal relationship between the study product and the adverse event. Thresholds for severity include events require minimal or no treatment and do not interfere with the subject's daily activities (mild), events result in a low level of inconvenience or concern with therapeutic measures and may cause some interference with functioning and daily activities (moderate), and events interrupt the subject's daily activities and may require systemic drug therapy or other treatment and are usually incapacitating (severe). Participants are counted once per preferred term and are summarized according to their highest severity. No severe events were reported.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Acne	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Taste Disorder	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Any Event	Mild	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Rash	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Acne	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Rash	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Muscle Spasms	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Acne	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Muscle Spasms	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Any Event	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Muscle Spasms	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus Congestion	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus Congestion	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Rash	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus Congestion	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Any Event	None	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Cough	None	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Cough	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Cough	Mild	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	Moderate	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	Mild	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Taste Disorder	None	21 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	Moderate	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Taste Disorder	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Acne	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Any Event	Mild	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Any Event	Moderate	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	None	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	Moderate	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Muscle Spasms	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Muscle Spasms	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Muscle Spasms	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Taste Disorder	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Taste Disorder	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Taste Disorder	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Cough	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Cough	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Cough	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	Mild	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	None	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus Congestion	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus Congestion	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus Congestion	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Acne	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Any Event	None	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Acne	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	None	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Rash	Mild	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Rash	Moderate	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Rash	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Rash	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Taste Disorder	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Acne	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Taste Disorder	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Cough	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Cough	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Cough	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Any Event	None	15 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Rash	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Any Event	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus Congestion	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Rash	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus Congestion	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Muscle Spasms	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Muscle Spasms	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus Congestion	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Muscle Spasms	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Any Event	Mild	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Acne	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	Mild	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	Mild	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Acne	Moderate	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	None	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	None	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)	Taste Disorder	Mild	0 Participants

Primary

Number of Participants Reporting Serious Adverse Events (SAEs)

SAEs included any AE that resulted in death, a life-threatening event, an inpatient hospitalization or prolongation of existing hospitalization, a persistent/significant disability/incapacity, or a congenital anomaly/birth defect.

Time frame: Day 1 to Day 182

Population: Safety Population: includes all participants who received at least one study vaccination

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Serious Adverse Events (SAEs)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Serious Adverse Events (SAEs)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Serious Adverse Events (SAEs)	0 Participants

Primary

Number of Participants Reporting Solicited Local Reactogenicity

Local reactogenicity solicited on a memory aid provided to participants included pain, tenderness, erythema (redness) (functional grade based on interference with daily activities), induration (hardness/swelling) (functional grade), ecchymosis (bruising) (functional grade), pruritus (itching), erythema (redness) (any measured value), induration (hardness/swelling) (any measured value), ecchymosis (bruising) (any measured value). Participants are considered reporting the local reactogenicity if they reported mild or greater severity at any time during the 7 days post-vaccination.

Time frame: Day 1 to Day 8 Post First Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination. All participants in all Study Arms received the same product (ChAd3-EBO-Z) at Day 1.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Functional Grade)	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Tenderness	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Measurement Grade)	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Functional Grade)	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Measurement Grade)	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Pruritus	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Any Local Symptom	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Functional Grade)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Pain	13 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Measurement Grade)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Pain	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Pruritus	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Functional Grade)	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Measurement Grade)	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Tenderness	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Measurement Grade)	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Functional Grade)	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Any Local Symptom	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Functional Grade)	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Measurement Grade)	7 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Functional Grade)	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Measurement Grade)	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Any Local Symptom	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Tenderness	15 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Pruritus	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Pain	14 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Measurement Grade)	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Functional Grade)	11 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Measurement Grade)	11 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Functional Grade)	5 Participants

Primary

Number of Participants Reporting Solicited Local Reactogenicity

Local reactogenicity solicited on a memory aid provided to participants included pain, tenderness, erythema (redness) (functional grade based on interference with daily activities), induration (hardness/swelling) (functional grade), ecchymosis (bruising) (functional grade), pruritus (itching), erythema (redness) (any measured value), induration (hardness/swelling) (any measured value), ecchymosis (bruising) (any measured value). Subjects are considered reporting the local reactogenicity if they reported mild or greater severity at any time during the 7 days post-vaccination.

Time frame: Day 1 to Day 15

Population: Safety Population: includes all participants who received at least one study vaccination.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (functional grade)	10 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Tenderness	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (functional grade)	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (functional grade)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Pruritus	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Any Local Symptom	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (measurement grade)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (measurement grade)	10 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Pain	13 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (measurement grade)	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (functional grade)	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (functional grade)	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Any Local Symptom	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Pain	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Tenderness	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Pruritus	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (measurement grade)	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (measurement grade)	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Induration (functional grade)	8 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Induration (measurement grade)	8 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Pain	14 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (functional grade)	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Any Local Symptom	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (functional grade)	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (measurement grade)	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (measurement grade)	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Pruritus	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Tenderness	15 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (functional grade)	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (measurement grade)	2 Participants

Primary

Number of Participants Reporting Solicited Local Reactogenicity

Time frame: Day 1 to Day 8 Post Second Vaccination

Population: Safety Population Subset: includes all participants who received the first and second study vaccination

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Measurement Grade)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Pruritus	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Functional Grade)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Functional Grade)	5 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Functional Grade)	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Pain	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Any Local Symptom	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Measurement Grade)	5 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Tenderness	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Measurement Grade)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Functional Grade)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Any Local Symptom	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Pain	13 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Tenderness	15 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Pruritus	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Measurement Grade)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Functional Grade)	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Measurement Grade)	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Functional Grade)	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Measurement Grade)	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Measurement Grade)	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Functional Grade)	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Pain	5 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Induration (Functional Grade)	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Erythema (Measurement Grade)	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Pruritus	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Functional Grade)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Tenderness	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Any Local Symptom	13 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Local Reactogenicity	Ecchymosis (Measurement Grade)	0 Participants

Primary

Number of Participants Reporting Solicited Systemic Reactogenicity

Systemic reactogenicity solicited on a memory aid provided to participants included feverishness (chills/shivering/sweating), malaise (general unwell feeling), fatigue (tiredness), myalgia (body aches/muscular pain not at injection site), headache, nausea, loss of appetite, and elevated oral temperature. Participants are considered reporting the systemic reactogenicity if they reported mild or greater severity at any time during the 7 days post-vaccination.

Time frame: Day 1 to Day 15

Population: Safety Population: includes all participants who received at least one study vaccination.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Malaise	14 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Loss of Appetite	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Myalgia	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Fatigue	18 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Nausea	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Elevated Oral Temperature	11 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Any Systemic Symptom	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Headache	13 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Feverishness	18 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Feverishness	16 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Any Systemic Symptom	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Elevated Oral Temperature	12 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Malaise	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Fatigue	19 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Myalgia	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Headache	13 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Nausea	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Loss of Appetite	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Elevated Oral Temperature	9 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Feverishness	13 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Headache	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Any Systemic Symptom	15 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Loss of Appetite	8 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Fatigue	13 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Malaise	13 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Nausea	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Myalgia	12 Participants

Primary

Number of Participants Reporting Solicited Systemic Reactogenicity

Time frame: Day 1 to Day 8 Post Second Vaccination

Population: Safety Population Subset: includes all participants who received the first and second study vaccination

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Myalgia	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Any Systemic Symptom	8 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Elevated Oral Temperature	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Feverishness	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Malaise	3 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Fatigue	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Headache	7 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Nausea	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Loss of Appetite	3 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Nausea	4 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Myalgia	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Malaise	14 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Feverishness	11 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Headache	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Any Systemic Symptom	14 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Loss of Appetite	7 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Fatigue	14 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Elevated Oral Temperature	8 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Loss of Appetite	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Feverishness	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Malaise	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Nausea	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Elevated Oral Temperature	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Fatigue	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Myalgia	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Any Systemic Symptom	6 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Headache	4 Participants

Primary

Number of Participants Reporting Solicited Systemic Reactogenicity

Time frame: Day 1 to Day 8 Post First Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination. All participants in all Study Arms received the same product (ChAd3-EBO-Z) at Day 1.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Malaise	13 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Loss of Appetite	4 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Myalgia	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Fatigue	17 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Any Systemic Symptom	20 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Nausea	6 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Feverishness	15 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Elevated Oral Temperature	11 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Solicited Systemic Reactogenicity	Headache	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Fatigue	15 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Any Systemic Symptom	20 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Elevated Oral Temperature	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Feverishness	14 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Malaise	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Myalgia	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Headache	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Nausea	9 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Solicited Systemic Reactogenicity	Loss of Appetite	9 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Feverishness	13 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Any Systemic Symptom	15 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Headache	12 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Elevated Oral Temperature	9 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Loss of Appetite	8 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Fatigue	13 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Malaise	13 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Nausea	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Solicited Systemic Reactogenicity	Myalgia	12 Participants

Primary

Number of Participants Reporting Vaccine-related Medically Attended Adverse Events (MAAEs)

Vaccine-related MAAEs include any AEs for which the participant received medical attention, defined as hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel for any reason for which there is evidence to suggest a causal relationship between the study product and the adverse event.

Time frame: Day 1 to Day 182

Population: Safety Population: includes all participants who received at least one study vaccination.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Medically Attended Adverse Events (MAAEs)	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Medically Attended Adverse Events (MAAEs)	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Medically Attended Adverse Events (MAAEs)	0 Participants

Primary

Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)

Vaccine-related unsolicited AEs include any untoward medical occurrence in a participant for which there is evidence to suggest a causal relationship between the study product and the adverse event.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Taste disorder	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Muscle spasms	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Acne	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Rash	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Sinus congestion	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Any SOC	4 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Cough	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	0 Participants
ChAd3-EBO-Z + Placebo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Any SOC	10 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Muscle spasms	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Taste disorder	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Cough	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Sinus congestion	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Acne	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Rash	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Ecchymosis	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Sinus headache	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Chest discomfort	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Acne	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Taste disorder	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Vomiting	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Any SOC	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Cough	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Oropharyngeal pain	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Tachycardia	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Rash	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Sinus congestion	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Back pain	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Dehydration	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Lymphadenopathy	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Muscle spasms	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Transaminases increased	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Diarrhea	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Dizziness	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)	Blood pressure diastolic decreased	1 Participants

Primary

Number of Participants With Clinical Safety Laboratory Adverse Events

Laboratory parameters include white blood cells (WBC), hemoglobin, platelet count, absolute neutrophil count, alanine aminotransferase (ALT), creatinine, sodium, potassium and blood urea nitrogen (BUN). Thresholds for adverse events were considered as WBC \<= 4.4 K/mcL or \>=13.1 K/mcL (18 to \<21 years) or \<= 4.4 K/mcL or \>= 11.1 K/mcL (\>=21 years), hemoglobin \<= 11.6 g/dL (female) or \<= 13.2 g/dL (male), platelet count \<= 134 K/mcL or \>= 467 K/mcL, absolute neutrophil count \<1.8 K/mcL or \<=0.7 K/mcL (benign ethnic neutropenia), ALT \>= 50 unit/L, creatinine \>= 0.81 mg/dL (female) or \>= 1.11 mg/dL (male), sodium \<= 135 mmol/L or \>= 146 mmol/L, potassium \<= 3.4 mmol/L or \>= 5.2 mmol/L and BUN \>= 24 mg/dL. If baseline clinical labs fell within Mild range, then a laboratory AE was reported only if the value changed such that it fell into Moderate range or higher when subsequent safety laboratory testing was done.

Time frame: Day 1 to approximately 28 Days Post Second Vaccination

Population: Safety Population: includes all participants who received at least one study vaccination.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Number of Participants With Clinical Safety Laboratory Adverse Events	Creatinine	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants With Clinical Safety Laboratory Adverse Events	WBC	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants With Clinical Safety Laboratory Adverse Events	Hemoglobin	2 Participants
ChAd3-EBO-Z + Placebo	Number of Participants With Clinical Safety Laboratory Adverse Events	Platelet count	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants With Clinical Safety Laboratory Adverse Events	Absolute neutrophil count	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants With Clinical Safety Laboratory Adverse Events	ALT	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants With Clinical Safety Laboratory Adverse Events	Sodium	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants With Clinical Safety Laboratory Adverse Events	Potassium	1 Participants
ChAd3-EBO-Z + Placebo	Number of Participants With Clinical Safety Laboratory Adverse Events	BUN	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants With Clinical Safety Laboratory Adverse Events	ALT	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants With Clinical Safety Laboratory Adverse Events	Sodium	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants With Clinical Safety Laboratory Adverse Events	WBC	5 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants With Clinical Safety Laboratory Adverse Events	Potassium	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants With Clinical Safety Laboratory Adverse Events	Creatinine	1 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants With Clinical Safety Laboratory Adverse Events	Hemoglobin	6 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants With Clinical Safety Laboratory Adverse Events	Absolute neutrophil count	5 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants With Clinical Safety Laboratory Adverse Events	BUN	0 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Number of Participants With Clinical Safety Laboratory Adverse Events	Platelet count	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants With Clinical Safety Laboratory Adverse Events	BUN	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants With Clinical Safety Laboratory Adverse Events	Absolute neutrophil count	3 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants With Clinical Safety Laboratory Adverse Events	Potassium	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants With Clinical Safety Laboratory Adverse Events	ALT	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants With Clinical Safety Laboratory Adverse Events	Creatinine	2 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants With Clinical Safety Laboratory Adverse Events	Platelet count	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants With Clinical Safety Laboratory Adverse Events	WBC	4 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants With Clinical Safety Laboratory Adverse Events	Sodium	0 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Number of Participants With Clinical Safety Laboratory Adverse Events	Hemoglobin	2 Participants

Secondary

Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population

The endpoint assessed antibodies against Ebola virus (EBOV) glycoproteins (GP) using an enzyme-linked immunosorbent assay (anti-EBOV GP ELISA). Venous blood samples for serum were used for this assay. Geometric mean fold rise (GMFR) compared to baseline (Day 1) was calculated for each study arm.

Time frame: Day 8, 15, 22, 29 and 36 compared to baseline (Day 1) reported as Day 8 post-first vaccination, Day 8 post-second vaccination, Day 15 post-second vaccination, Day 22 post-second vaccination, and Day 29 post-second vaccination, respectively.

Population: ITT Population: includes all participants who received at least one study vaccination and contributed both pre- and at least one post-study vaccination blood samples for immunogenicity testing for which valid results were reported

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
ChAd3-EBO-Z + Placebo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 22 Post-Second Vaccination	70.7 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 15 Post-Second Vaccination	54.3 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-First Vaccination (Second Vaccination)	1.1 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-Second Vaccination	21.5 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 29 Post-Second Vaccination	83.3 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 15 Post-Second Vaccination	54.9 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-First Vaccination (Second Vaccination)	1.2 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-Second Vaccination	21.0 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 22 Post-Second Vaccination	77.6 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 29 Post-Second Vaccination	97.8 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 29 Post-Second Vaccination	82.6 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 22 Post-Second Vaccination	74.1 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-First Vaccination (Second Vaccination)	1.3 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 15 Post-Second Vaccination	49.6 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-Second Vaccination	25.4 titer

Secondary

Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population

Population: Per Protocol population includes all participants who received at least one study vaccination, contributed both pre- and at least one post-study vaccination blood samples for immunogenicity testing for which valid results were reported, were eligible at baseline and have no major protocol deviations.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
ChAd3-EBO-Z + Placebo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 22 Post-Second Vaccination	75.3 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 15 Post-Second Vaccination	61.3 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 8 Post-First Vaccination (Second Vaccination)	1.1 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 8 Post-Second Vaccination	25.1 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 29 Post-Second Vaccination	92.4 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 15 Post-Second Vaccination	45.3 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 8 Post-First Vaccination (Second Vaccination)	1.2 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 8 Post-Second Vaccination	17.4 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 22 Post-Second Vaccination	66.8 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 29 Post-Second Vaccination	83.0 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 29 Post-Second Vaccination	66.7 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 22 Post-Second Vaccination	64.0 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 8 Post-First Vaccination (Second Vaccination)	1.3 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 15 Post-Second Vaccination	43.5 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population	Day 8 Post-Second Vaccination	23.1 titer

Secondary

Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population

Time frame: Day 1, 8, 15, 22, 29 and 36 reported as Day 1 first vaccination, Day 8 post-first vaccination, Day 8 post-second vaccination, Day 15 post-second vaccination, Day 22 post-second vaccination, and Day 29 post-second vaccination, respectively.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 1 First Vaccination	29.5 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-First Vaccination (Second Vaccination)	32.6 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-Second Vaccination	635.0 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 15 Post-Second Vaccination	1600.0 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 22 Post-Second Vaccination	2083.5 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 29 Post-Second Vaccination	2457.4 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 29 Post-Second Vaccination	3325.6 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 1 First Vaccination	33.5 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 15 Post-Second Vaccination	1866.4 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 22 Post-Second Vaccination	2639.6 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-First Vaccination (Second Vaccination)	40.2 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-Second Vaccination	712.7 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-First Vaccination (Second Vaccination)	35.4 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-Second Vaccination	831.4 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 29 Post-Second Vaccination	2666.4 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 15 Post-Second Vaccination	1600.0 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 1 First Vaccination	32.3 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population	Day 22 Post-Second Vaccination	2390.0 titer

Secondary

Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 1 First Vaccination	29.5 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-First Vaccination (Second Vaccination)	32.6 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-Second Vaccination	679.6 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 15 Post-Second Vaccination	1670.8 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 22 Post-Second Vaccination	2043.5 titer
ChAd3-EBO-Z + Placebo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 29 Post-Second Vaccination	2505.6 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 29 Post-Second Vaccination	2810.0 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 1 First Vaccination	33.5 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 15 Post-Second Vaccination	1532.2 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 22 Post-Second Vaccination	2262.7 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-First Vaccination (Second Vaccination)	40.2 titer
ChAd3-EBO-Z + ChAd3-EBO-Z	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-Second Vaccination	590.7 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-First Vaccination (Second Vaccination)	35.4 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-Second Vaccination	768.0 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 29 Post-Second Vaccination	2217.1 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 15 Post-Second Vaccination	1425.4 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 1 First Vaccination	32.3 titer
ChAd3-EBO-Z + MVA- BN-Filo	Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 22 Post-Second Vaccination	2128.5 titer

Secondary

Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population

The endpoint assessed antibodies against Ebola virus (EBOV) glycoproteins (GP) using an enzyme-linked immunosorbent assay (anti-EBOV GP ELISA). Venous blood samples for serum were used for this assay. Seroconversion was calculated for each study arm and was defined as anti-EBOV GP ELISA titer \> 50 if baseline (Day 1) titer = 50 or fold rise \> 4 as compared to baseline if baseline titer \> 50.

Time frame: Day 8, 15, 22, 29 and 36 reported as Day 8 post-first vaccination, Day 8 post-second vaccination, Day 15 post-second vaccination, Day 22 post-second vaccination, and Day 29 post-second vaccination, respectively.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 22 Post-Second Vaccination	21 Participants
ChAd3-EBO-Z + Placebo	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 15 Post-Second Vaccination	21 Participants
ChAd3-EBO-Z + Placebo	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-First Vaccination (Second Vaccination)	1 Participants
ChAd3-EBO-Z + Placebo	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-Second Vaccination	20 Participants
ChAd3-EBO-Z + Placebo	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 29 Post-Second Vaccination	21 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 15 Post-Second Vaccination	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-First Vaccination (Second Vaccination)	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-Second Vaccination	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 22 Post-Second Vaccination	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 29 Post-Second Vaccination	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 29 Post-Second Vaccination	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 22 Post-Second Vaccination	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-First Vaccination (Second Vaccination)	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 15 Post-Second Vaccination	19 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population	Day 8 Post-Second Vaccination	17 Participants

Secondary

Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population

The endpoint assessed antibodies against Ebola virus (EBOV) glycoproteins (GP) using an enzyme-linked immunosorbent assay (anti-EBOV GP ELISA). Venous blood samples for serum were used for this assay. Seroconversion was calculated for each study arm and was defined as anti-EBOV GP ELISA titer \> 50 if baseline (Day 1) titer = 50 or fold rise \> 4 as compared to baseline if baseline titer \> 50.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
ChAd3-EBO-Z + Placebo	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 22 Post-Second Vaccination	17 Participants
ChAd3-EBO-Z + Placebo	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 15 Post-Second Vaccination	16 Participants
ChAd3-EBO-Z + Placebo	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-First Vaccination (Second Vaccination)	1 Participants
ChAd3-EBO-Z + Placebo	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-Second Vaccination	17 Participants
ChAd3-EBO-Z + Placebo	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 29 Post-Second Vaccination	17 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 15 Post-Second Vaccination	15 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-First Vaccination (Second Vaccination)	2 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-Second Vaccination	15 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 22 Post-Second Vaccination	15 Participants
ChAd3-EBO-Z + ChAd3-EBO-Z	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 29 Post-Second Vaccination	16 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 29 Post-Second Vaccination	16 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 22 Post-Second Vaccination	16 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-First Vaccination (Second Vaccination)	1 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 15 Post-Second Vaccination	18 Participants
ChAd3-EBO-Z + MVA- BN-Filo	Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population	Day 8 Post-Second Vaccination	16 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Absolute Neutrophil Count

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - ALT

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - BUN

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Creatinine (Increase)

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Hemoglobin

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Platelet Count

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Potassium

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - Sodium

Number of Participants by Severity of Clinical Safety Laboratory Adverse Events - White Blood Cells

Number of Participants by Severity of Solicited Local Reactogenicity

Number of Participants by Severity of Solicited Local Reactogenicity

Number of Participants by Severity of Solicited Local Reactogenicity

Number of Participants by Severity of Solicited Systemic Reactogenicity

Number of Participants by Severity of Solicited Systemic Reactogenicity

Number of Participants by Severity of Solicited Systemic Reactogenicity

Number of Participants by Severity of Vaccine-related Unsolicited Adverse Events (AEs)

Number of Participants Reporting Serious Adverse Events (SAEs)

Number of Participants Reporting Solicited Local Reactogenicity

Number of Participants Reporting Solicited Local Reactogenicity

Number of Participants Reporting Solicited Local Reactogenicity

Number of Participants Reporting Solicited Systemic Reactogenicity

Number of Participants Reporting Solicited Systemic Reactogenicity

Number of Participants Reporting Solicited Systemic Reactogenicity

Number of Participants Reporting Vaccine-related Medically Attended Adverse Events (MAAEs)

Number of Participants Reporting Vaccine-related Unsolicited Adverse Events (AEs)

Number of Participants With Clinical Safety Laboratory Adverse Events

Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - ITT Population

Geometric Mean Fold Rise (GMFR) as Measured by Anti-EBOV GP ELISA - Per Prototocol Population

Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - ITT Population

Geometric Mean Titer (GMT) as Measured by Anti-EBOV GP ELISA - Per Protocol Population

Seroconversion as Measured by Anti-EBOV GP ELISA - ITT Population

Seroconversion as Measured by Anti-EBOV GP ELISA - Per Protocol Population